ArticleFrontiers in cardiovascular medicine2026
Combined MitraClip and TriClip therapy in patients with severe mitral and tricuspid regurgitation: determinants and prediction of mid-term outcomes.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with combined severe mitral (MR) and tricuspid regurgitation (TR) constitute a high-risk cohort with advanced right-heart disease, reduced survival, and frequent heart failure hospitalizations. While transcatheter edge-to-edge repair (TEER) is guideline-endorsed for severe MR and increasingly adopted for TR, long-term evidence on combined dual-valve TEER remains limited. The TRIVALVE score has shown prognostic utility in transcatheter tricuspid interventions but has not been specifically evaluated in patients requiring combined TEER. Methods: We prospectively enrolled 54 consecutive patients with severe MR and TR undergoing combined TEER by means of MitraClip® and TriClip®. Baseline clinical, echocardiographic, and laboratory data were collected. The primary endpoint was all-cause mortality; the secondary endpoint was a composite endpoint of all-cause mortality or heart failure rehospitalization (cumulative events). Survival and cumulative events were estimated by Kaplan-Meier analysis, determinants were identified by logistic regression, and prediction models were built using random-forest, logistic regression, and gradient boosting. Results: Median TRIVALVE score was 2.0 (IQR 1.0-3.0) and median EuroSCORE II was 4.5 (IQR: 3.0-7.6). Thirty-day mortality was 5.5% (3/54). Median clinical follow-up was 607 days (IQR 289-906). Estimated 1-year and 2-year survival was 91.8% and 64.5%, with 74.2% and 52.7% freedom from mortality or heart failure rehospitalization. In the regression analysis, both TRIVALVE score (OR=2.19; 95% CI: 1.06-4.53; Conclusion: Combined dual-valve TEER achieved acceptable mid-term survival and event-free outcomes. Outcomes were driven more by baseline disease burden than by procedural success alone. Lower baseline hemoglobin and a higher TRIVALVE score were both linked to worse prognosis, with atrial fibrillation and right heart failure as its most influential components, highlighting the contribution of chronic atrial remodeling and congestion to recurrent events. These findings are hypothesis-generating and require external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.